natgillin/translations-raw huggingface dataset:
Throughout clinical trials data from a limited number of exposed pregnancies (22) indicate that there is no clinical evidence that treatment with Vaniqa adversely affects mothers or foetuses. 
Klinične študije z omejenim številom nosečnic, izpostavljenih zdravilu Vaniqa (22), ne dajejo kliničnih dokazov, da je jemanje zdravila škodljivo za mater ali plod.
In such cases they normally resolve without discontinuation of Vaniqa. 
V takih primerih običajno minejo brez prekinitve zdravljenja z zdravilom Vaniqa.
B CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 
B POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE
Among the 22 pregnancies that occurred during the trials, only 19 pregnancies occurred while the patient was using Vaniqa. 
Med 22 nosečnostmi med študijo je samo 19 žensk zanosilo med uporabo zdravila Vaniqa.
Other medicines and Vaniqa 
Druga zdravila in zdravilo Vaniqa
A thin layer of the cream should be applied to clean and dry affected areas. 
Način uporabe Tanek sloj kreme je treba nanesti na čisto in suho kožo prizadetih predelov.
Side effects are usually limited to the skin and mild in intensity. 
Neželeni učinki so navadno omejeni na kožo in po jakosti blagi.
If skin irritation or intolerance develops, the frequency of application should be reduced temporarily to once a day. 
V primeru draženja kože ali intolerance na mestu nanosa začasno zmanjšajte pogostnost nanašanja na enkrat dnevno.
• If you experience irritation (e.g. stinging burning), reduce the use of Vaniqa to once daily until the irritation has gone. 
• Če pride do draženja kože (npr. občutek zbadanja, pekoč občutek), zmanjšajte uporabo zdravila Vaniqa na enkrat dnevno, dokler draženje ne preneha.
Subgroup analysis also showed that 29% of obese women (BMI ≥ 30) and 43% of normal weight women (BMI < 30) showed a marked or better improvement. 
V analizi podskupin se je pokazala tudi razlika med prekomerno prehranjenimi ženskami (BMI ≥ 30), kjer je prišlo do izboljšanja pri 29 % in tistimi z normalno telesno maso (BMI < 30), kjer je prišlo do izboljšanja pri 43 % žensk.
White to off white cream 
krema bela do umazano bela krema
Contents of the pack and other information What Vaniqa contains 
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Vaniqa
C OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION 
C DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM
EXP Discard the tube 6 months after opening. 
Uporabno do: Tubo zavrzite 6 mesecev po odprtju.
• Apply a thin layer of cream and rub it in thoroughly until no visual residual product remains on the treated areas. 
• Nanesite tanek sloj te kreme in dobro vtirajte, dokler na zdravljenih predelih ni več vidnih preostankov zdravila.
Make sure the cap of the tube is tightly closed after each use. 
Po vsaki uporabi tesno zaprite pokrovček.
Therefore, women who are pregnant or planning pregnancy should use an alternative means to manage facial hair. 
Zato ženske, ki so noseče ali načrtujejo nosečnost, pri prekomerni poraščenosti obraza odstranjujejo dlake na drugačen način.
Tiny amounts of sodium hydroxide (E524) are sometimes added to keep acidity levels (pH levels) normal. 
Včasih so dodane majhne količine natrijevega hidroksida (E524) za ohranjanje normalne kislosti (pH vrednosti).
CLINICAL PARTICULARS 4.1 Therapeutic indication 
4.1 Terapevtske indikacije
• Wash your hands after applying the cream. 
• Po uporabi te kreme si umijte roke.
Discard the opened tube with any remaining cream after 6 months. 
Odprto tubo s preostalo kremo zavrzite 6 mesecev po prvem odprtju.
Talk to your doctor if you need to use other medicines on the areas of skin where you are using the cream. 
Obvestite svojega zdravnika, če uporabljate katero koli zdravilo na predelih kože, kjer uporabljate zdravilo Vaniqa.
• If you have just shaved or used any other hair removal method, wait at least 5 minutes before using Vaniqa. 
• Po britju ali odstranjevanju dlak počakajte vsaj 5 minut pred uporabo zdravila Vaniqa.
What Vaniqa is and what it is used for 
Kaj je zdravilo Vaniqa in za kaj ga uporabljamo
Vaniqa has no or negligible influence on the ability to drive and use machines. 
Zdravilo Vaniqa nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Common (≥1/100 to <1/10) 
(≥1/100 do <1/10)
Each gram of cream contains 47.2 mg of cetostearyl alcohol, 14.2 mg of stearyl alcohol, 0.8 mg of methyl parahydroxybenzoate and 0.32 mg of propyl parahydroxybenzoate. 
1 gram kreme vsebuje 47,2 mg cetil in stearilalkohola, 14,2 mg stearilalkohola, 0,8 mg metilparahidroksibenzoata in 0,32 mg propilparahidroksibenzoata.
What you need to know before you use Vaniqa Do not use Vaniqa: 
Kaj morate vedeti, preden boste uporabili zdravilo Vaniqa Ne uporabljajte zdravila Vaniqa:
In a dermal fertility study in rats, no adverse effects on fertility were observed at up to 180 times the human dose. 
V dermalnih fertilnostnih študijah pri podganah niso opazili škodljivih učinkov na fertilnost tudi pri 180-krat višjih odmerkih kot pri ljudeh.
Vaniqa is for cutaneous use only. 
Zdravilo Vaniqa je le za dermalno uporabo.
High density polyethylene tube with a polypropylene screw cap containing 15 g, 30 g or 60 g of cream. 
Polietilenska tuba visoke gostote s polipropilensko navojnim pokrovčkom, ki vsebuje 15 g, 30 g, ali
Vaniqa contains the active substance eflornithine. 
Zdravilo Vaniqa vsebuje zdravilno učinkovino eflornitin.
The steady state 12-hour area under the plasma concentration versus time curve was 92.5 ng.hr/ml. 
12 urna površina pod krivuljo plazemske koncentracije v odvisnosti od časa v stanju dinamičnega ravnovesja je 92,5 ng h/ml.
Eflornithine is not known to be metabolised and is eliminated primarily in the urine. 
Eflornitin se ne presnavlja in se izloča z urinom.
Improvement was seen as early as 8 weeks after initiation of treatment. 
Izboljšanje so opazili že po 8 tednih po začetku zdravljenja.
Uncommon (≥1/1,000 to <1/100) 
Občasno (≥1/1.000 do <1/100)
Vaniqa contains cetostearyl alcohol and stearyl alcohol which may cause local skin reactions (e.g. contact dermatitis). 
Vaniqa vsebuje cetil in stearilalkohol in stearilalkohol, ki lahko povzroči lokalne reakcije na koži (npr. kontaktni dermatitis).
Cosmetics (including sunscreens) can be applied over the treated areas, but no sooner than five minutes after application. 
Preko predelov, kamor ste nanesli zdravilo, lahko nanašate kozmetične preparate (vključno s kremami za sončenje), vendar ne prej kot v petih minutah po nanosu zdravila.
As the safety of Vaniqa has not been studied in patients with severe renal impairment, caution should be used when prescribing Vaniqa for these patients. 
Varnost uporabe zdravila Vaniqa pri hudi ledvični okvari ni bila ugotovljena, zato je pri teh bolnikih potrebna previdnost pri uporabi zdravila Vaniqa.
If you or anyone else accidentally swallows Vaniqa, contact your doctor immediately. 
Če ste po nesreči, vi ali kdorkoli drug, zaužili zdraviloVaniqa, se nemudoma posvetujte z zdravnikom.
Vaniqa cream should be applied to the affected area twice daily, at least eight hours apart. 
Odmerjanje Zdravilo Vaniqa je treba nanesti dvakrat dnevno v vsaj osemurnih presledkih na kožo prizadetega predela.
The active substance is eflornithine. 
Učinkovina je eflornitin.
If you stop using Vaniqa 
Če ste prenehali uporabljati zdravilo Vaniqa
The mostly skin related adverse reactions reported were primarily mild in intensity and resolved without discontinuation of Vaniqa or initiation of medical treatment. 
Večina s kožo povezanih neželenih učinkov je bilo blagih in so izzveneli brez prekinitve uporabe zdravila Vaniqa ali uporabe zdravil.
Vaniqa also contains methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed). 
Vaniqa vsebuje tudi metilparahidroksibenzoat (E218) in propilparahidroksibenzoat (E216), ki lahko povzročita alergijske reakcije (lahko zapoznele).
D CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
D POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO
These factors should be considered in the overall medical treatment of patients who might be prescribed Vaniqa. 
Ta obolenja je potrebno upoštevati pri zdravljenju bolnikov, ki jim predpišemo zdravilo Vaniqa.
Contact with eyes or mucous membranes (e.g. nose or mouth) should be avoided. 
Izogibajte se kontaktu z očmi ali sluznicami (npr. nos ali usta).
The following listing notes the frequency of adverse skin reactions seen in clinical trials, according to MedDRA convention. 
Seznam pogostnosti neželenih kožnih reakcij v kliničnih študijah po MedDRA konvenciji.
What Vaniqa looks like and the contents of the pack 
Izgled zdravila Vaniqa in vsebina pakiranja
MARKETING AUTHORISATION NUMBERS 
ŠTEVILKA DOVOLJENJA ZA PROMET
Non-clinical data reveal no special hazard for humans based on conventional studies of repeat dose toxicity, genotoxicity and carcinogenic potential, including one photocarcinogenicity study in mice. 
Predklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih, genotoksičnosti, kancerogenega potenciala, vključno z eno študijo fotokancerogenosti v miših ne kažejo posebnega tveganja za človeka.
The skin effects of burning, stinging, tingling, rash and erythema were reported at higher levels in Vaniqa treated patients compared to vehicle, as indicated by the asterisk (*). 
Kožne reakcije kot na primer mravljinčenje, zbadanje ali pekoč občutek, izpuščaj in eritem se pogosteje pojavljajo pri bolnikih zdravljenih z zdravilom Vaniqa, v primerjavi s tistimi, ki so prejemali le vehikel, kot je označeno z zvezdico (*).
Vaniqa significantly reduced how bothered patients felt by their facial hair and by the time spent removing, treating, or concealing facial hair. 
Zdravilo Vaniqa je pomembno zmanjšala nelagoden občutek zaradi obraznih dlak in čas, ki ga bolnice porabijo za odstranjevanje in prekrivanje obraznih dlak.
How to use Vaniqa 
Kako uporabljati zdravilo Vaniqa
However, should very high dose cutaneous administration or accidental oral ingestion occur, attention should be paid to the effects seen with therapeutic doses of intravenous eflornithine (400 mg/kg/day or approximately 24 g/day) used in the treatment of Trypanosoma brucei gambiense infection (African sleeping sickness): hair loss, facial swelling, seizures, hearing impairment, gastrointestinal disturbance, loss of appetite, headache, weakness, dizziness, anaemia, thrombocytopenia and leucopenia. 
Vendar pa moramo biti v primeru zelo visokih odmerkov pri dermalni aplikaciji ali zaužitju zdravila po pomoti pozorni na učinke, vidne pri intravenskem dajanju zdravila v terapevtskih odmerkih (400 mg/kg/dan ali približno 24 g/dan) pri zdravljenju infekcij s Trypanosoma brucei gambiense (afriška spalna bolezen): izguba las, otekanje obraza, krči, okvara sluha, prebavne motnje,
If you put too much cream on your skin, it is unlikely to harm you. 
Če ste uporabili več zdravila Vaniqa kot bi smeli Če ste nanesli preveč kreme, ni verjetno da vam bo škodilo.
Vaniqa is not expected to have any effect on your ability to drive or use machines. 
Vpliva zdravila Vaniqa na vašo sposobnost upravljanja vozil ali strojev ni pričakovati.
In dermal teratology studies, no teratogenic effects were observed in rats and rabbits at doses up to 180 and 36 times the human dose, respectively. 
V dermalnih teratoloških študijah na podganah in kuncih niso opazili teratogenih učinkov pri 180-krat (podgane) in 36-krat (kunci) višjih odmerkih kot pri ljudeh.
Of those with no acne at baseline, similar percentages (14%) reported acne following treatment with Vaniqa or vehicle. 
Pri bolnikih brez aken ob začetku študije se je aknavost pojavila v podobnem odstotku (14 %) tako pri tistih, ki so uporabljali zdravilo Vaniqa ali pa le vehikel.
Talk to your doctor if you suffer from polycystic ovary syndrome (PCOS) or specific hormone producing tumours, or if you take medicines that can induce hair growth, e.g. cyclosporine (following organ transplants), glucocorticoids (e.g. against rheumatic or allergic diseases), minoxidil (against high blood pressure), phenobarbitone (against seizures), phenytoin (against seizures) or hormone replacement therapy with male hormone like effects. 
Če bolehate za sindromom policističnih jajčnikov (PCOS) ali tumorji, ki proizvajajo specifičen hormon ali če jemljete zdravila, ki lahko povzročijo rast dlak, npr. ciklosporin (po transplantacijah organov), glukokortikoide (npr. proti revmatskim ali alergijskim obolenjem), minoksidil (proti zvišanemu krvnemu tlaku), fenobarbiton
Women should not use Vaniqa whilst breastfeeding. 
Med dojenjem se zdravila Vaniqa ne sme uporabljati.
If irritation continues, treatment should be discontinued and the physician consulted. 
Če draženje ne preneha, prekinite terapijo in se posvetujte z zdravnikom.
Very common (affects more than 1 user in 10) 
Zelo pogosto (pojavijo se pri več kot 1 bolnici od 10 bolnic)
Apply straight away, but wait at least 8 hours before using it again. 
Če ste pozabili uporabiti zdravilo Vaniqa Uporabite jo takoj, vendar počakajte vsaj 8 ur pred naslednjim nanosom.
• If possible, do not wash these areas of skin for 4 hours after applying the cream 
• Mesta, kjer ste nanesli to kremo, ne umivajte vsaj 4 ure po nanosu.
A MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJE
The steady state peak and trough plasma concentrations of eflornithine were approximately 10 ng/ml and 5 ng/ml, respectively. 
Najvišja koncentracija in najnižja koncentracija pred naslednjim odmerkom v stanju dinamičnega ravnovesja sta 10 ng/ml in 5 ng/ml.
Sodium hydroxide (E524) (to adjust pH) 
stearilalkohol; natrijev hidroksid (E524) (za prilagoditev pH).
The condition returned to pre-treatment levels within eight weeks after discontinuation of treatment. 
Bolezen se je vrnila na osnovno stanje po 8 tednih po prekinitvi zdravljenja.
In that case, the cream should be applied no sooner than five minutes after shaving or use of other hair removal methods, as increased stinging or burning may otherwise occur. 
V teh primerih zdravilo nanesite pet minut po odstranitvi dlak, saj se lahko na teh predelih pojavi zbadajoč ali pekoč občutek.
Also contains: cetostearyl alcohol; macrogol cetostearyl ether; dimeticone; glyceryl stearate; macrogol stearate; methyl parahydroxybenzoate (E218); liquid paraffin; phenoxyethanol; propyl parahydroxybenzoate (E216); purified water; stearyl alcohol and sodium hydroxide (to adjust pH). 
Vsebuje tudi: cetil in stearilalkohol; makrogol cetil stearileter; dimetikon; glicerilstearat; makrogol stearat; metilparahidroksibenzoat (E218); mineralno olje; fenoksietanol; propilparahidroksibenzoat (E216); tekoči parafin; prečiščena voda; stearilalkohol in natrijev hidroksid (za prilagoditev pH).
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS TUBES 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH
Efficacy has only been demonstrated for affected areas of the face and under the chin. 
Učinkovitost je dokazana le za prizadete predele obraza in brade, zato zdravilo uporabljajte le na teh predelih.
Vaniqa 11.5% cream Vehicle 
Vaniqa 11,5 % krema Vehikel
Vaniqa 11.5% cream Eflornithine 
Vaniqa 11,5 % krema eflornitin
Do not use Vaniqa if you are pregnant or breast-feeding. 
Nosečnost in dojenje Če ste noseči ali dojite, ne uporabljajte zdravila Vaniqa.
Ingrown hair, oedema face, dermatitis, oedema mouth, papular rash, bleeding skin, herpes simplex, eczema, cheilitis, furunculosis, contact dermatitis, abnormal hair texture and abnormal hair growth, hypopigmentation, flushing skin, lip numbness, skin soreness 
vraščanje dlak, obrazni edem, dermatitis, edem ust, papulozni izpuščaj, krvaveča koža, herpes simplex, ekcem, heilitis, furunkuloza, kontaktni dermatitis, nenormalna sestava las, nenormalna rast las, hipopigmentacija,
The most frequently reported adverse reaction was acne, which was generally mild. 
Najpogostejši neželeni učinek so akne, ki so navadno blažje oblike.
Skin and subcutaneous tissue disorders 
Bolezni kože in podkožja Zelo pogosto akne
The safety and efficacy of Vaniqa was evaluated in two double-blind, randomised, vehicle-controlled clinical trials involving 596 women of skin types I-VI (395 on Vaniqa, 201 on vehicle) treated for up to 24 weeks. 
Sodelovalo je 596 žensk s tipom kože I-VI (395 jih je prejemalo zdravilo Vaniqa, 201 pa le vehikel).
Vaniqa 11.5% cream 
Vaniqa 11,5 % krema
Statistically significant (p ≤ 0.001) improvement for Vaniqa versus vehicle was seen in each of these studies for women with marked improvement and clear/almost clear responses. 
V obeh študijah so pokazali statistično značilno izboljšanje (p ≤ 0,001) in rezultat zdravljenja čisto/skoraj čisto pri uporabi zdravila Vaniqa v primerjavi z vehiklom.
In the vehicle controlled trials (n= 596), acne was observed in 41% of patients at baseline; 7% of patients treated with Vaniqa and 8% treated with vehicle experienced a worsening of their condition. 
V študijah, kontroliranih z vehiklom (n = 596), je imelo 41 % bolnikov akne ob začetku študije.
Subgroup analysis revealed a difference in treatment success where 27% of non-white women and 39% of white women showed a marked or better improvement. 
Analiza podskupin je pokazala razliko v uspehu zdravljenja pri belkah in ne-belkah.
o abnormal skin growth (skin neoplasm) o excessive hair growth o flushing, facial redness and pimples possibly with pus o other skin disorders o red, scaly and itchy skin inflammation (seborrhoeic dermatitis) o red, bumpy or blistering rash o skin cysts o skin tightness 
o nenormalna rast kože (neoplazma kože) o prekomerna rast dlak o zardevanje, obrazna rdečina, mozolji, morda z gnojem o druga kožna obolenja o rdeče, luskasto in srbeče vnetje kože (seboroični dermatitis) o rdeč, bulast ali mehurčast izpuščaj o kožne ciste o napetost kože
The medicinal product should be applied such that no visual residual product remains on the treated areas after rub-in. 
Zdravilo nanesite tako, da po vtiranju v kožo na prizadetih predelih ni ostankov kreme.
Vaniqa has been shown to reduce the rate of hair growth. 
Zdravilo Vaniqa upočasni rast las.
• if you are unsure whether or not to use this medicine contact your doctor or pharmacist for advice. 
• Če o uporabi zdravila niste prepričani, se posvetujte z zdravnikom ali farmacevtom.
Pseudofolliculitis barbae, alopecia, stinging skin*, burning skin*, dry skin, pruritus, erythema*, tingling skin*, irritated skin, rash*, folliculitis 
psevdofolikulitis barbae, alopecija, zbadanje na koži*, pekoč občutek na koži*, suha koža, pruritus, eritem*, mravljinčenje*, draženje kože, izpuščaj*,
• Clean and dry the areas of the skin where you will be using the cream. 
• Pred uporabo te kreme kožo očistite in posušite.
Contents of the pack and other information 
Shranjevanje zdravila Vaniqa Vsebina pakiranja in dodatne informacije
Patients may need to continue to use a hair removal method (e.g. shaving or plucking) in conjunction with Vaniqa. 
Pri nekaterih bolnikih je lahko potrebna, poleg zdravila Vaniqa, tudi nadaljnja uporaba metod odstranjevanja dlak (kot npr. britje ali puljenje).
Propyl parahydroxybenzoate (E216); Purified water; 
mineralno olje; fenoksietanol; propilparahidroksibenzoat (E216);
The combined results of these two trials are presented below: 
Rezultati obeh študij so prikazani v preglednici: Rezultat zdravljenja*
The other ingredients are: cetostearyl alcohol; macrogol cetostearyl ether; dimeticone; glyceryl stearate; macrogol stearate; methyl parahydroxybenzoate (E218); liquid paraffin; phenoxyethanol; propyl parahydroxybenzoate (E216); purified water and stearyl alcohol. 
Pomožne snovi so: cetil in stearilalkohol; makrogol cetil stearileter; dimetikon; glicerilstearat; makrogol stearat; metilparahidroksibenzoat (E218); mineralno olje; fenoksietanol; propilparahidroksibenzoat (E216);
(affects 1 to 10 users in 10,000) 
(pojavijo se pri 1 do 10 bolnic 10.000 bolnic)
Rare (affects 1 to 10 users in 10,000) 
Redko (pojavijo se pri 1 do 10 bolnic od 10.000 bolnic)
It may sting or burn if you put this cream on cut or irritated skin. 
Če nanesete to kremo na ranjeno ali vzdraženo kožo, lahko pride do občutka zbadanja ali pekočega občutka.
Name and address of the manufacturer responsible for batch release 
A IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJE Ime in naslov izdelovalca, odgovornega za sproščanje serij
- If you get any side effects, talk to your doctor or pharmacist. 
- Če opazite kateri koli neželeni učinek, se posvetujte s svojim s svojo zdravnikom ali s farmacevtom.
Frequency of adverse skin reactions seen in Vaniqa clinical trials, (according to MedDRA frequency convention). 
Pogostnost s kožo povezanih neželenih učinkov, opaženih v kliničnih študijah pri zdravilu Vaniqa (po
o bumpy rash (papular rash) o cold sores o redness and irritation at the site where the cream is applied o eczema o inflammed, dry, cracked or numb lips o ingrowing hairs o pale areas on the skin o skin bleeding o skin boils o skin flushing o skin inflammation o sore skin o swelling of the mouth or face o unusual hair texture or hair growth 
o bulast izpuščaj (papulozni izpuščaj) o vročinski mehurčki o rdečina in draženje na predelu, kjer je nanešena krema o ekcem o vnete, suhe, razpokane ali odrevenele ustnice o dlake, ki se vraščajo o bledi predeli na koži o kožne krvavitve o kožni ognojki o rdečica kože o vnetje kože o boleča koža o otekanje ust ali obraza o nenavadna struktura ali rast las
Improvement in the condition may be noticed within eight weeks of starting treatment. 
Izboljšanje stanja lahko pričakujete znotraj osmih tednov zdravljenja.
o dry skin o hair loss o inflammation around the hair shaft o itching o rash o redness o skin irritation and bumps caused by shaving o skin irritation o stinging, tingling or burning feeling on the skin 
o suha koža o izguba las o vnetje okoli lasu o srbenje o izpuščaj o rdečina o draženje kože in bule, ki jih povzroča britje o draženje kože o občutek zbadanja, mravljinčenje ali pekoč občutek na koži
Steady state cutaneous penetration of eflornithine in women from Vaniqa on facial skin of shaving women was 0.8%. 
Kožna penetracija eflornitina v stanju dinamičnega ravnovesja na koži obraza žensk, ki se brijejo je
These patientobservable differences were seen 8 weeks after initiating treatment. 
Spremembe, ki so jih opazili bolniki, so se pojavile po 8 tednih zdravljenja.
If it persists contact your doctor. 
Če ne mine, se posvetujte z zdravnikom.
(affects less than 1 user in 10,000) not known (frequency cannot be estimated from the available data). 
(ni mogoče oceniti iz razpoložljivih podatkov)
Physicians assessed the change from baseline on a 4-point scale, 48 hours after women had shaved the treated areas of the affected areas of the face and under the chin, considering parameters such as hair length and density, and darkening of the skin associated with the presence of terminal hair. 
Ocenjevali so parametre, kot je dolžina in gostota dlak, potemnitev kože povezane s prisotnostjo terminalnih dlak.
Cutaneous use 
za dermalno uporabo
For maximal efficacy, the treated area should not be cleansed within four hours of application. 
Predelov, kjer ste zdravilo nanesli, zaradi boljše učinkovitosti ne čistite vsaj še štiri ure po nanosu.
What you need to know before you use Vaniqa 3. 
Kaj je zdravilo Vaniqa in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Vaniqa Kako uporabljati zdravilo Vaniqa
Common (affects 1 to 10 users in 100) 
Pogosto (pojavijo se pri 1 do 10 bolnic od 100 bolnic)
Rosacea, seborrheic dermatitis, skin neoplasm, maculopapular rash, skin cysts, vesiculobullous rash, skin disorder, hirsutism, skin tightness 
(≥1/10.000 do rozacea, seboroični dermatitis, kožni rak, makulopapulozni izpuščaj, kožne ciste, vezikulobulozni izpuščaj, bolezni kože, hirsuitizem, napetost kože